Quoin Pharmaceuticals Reports Positive Phase 2/3 Data for Netherton Syndrome Treatment

Quoin Pharmaceuticals announced encouraging interim results from its ongoing clinical trial of QRX003, a potential therapy for the rare genetic skin disorder Netherton Syndrome.